Scholar Rock stock falls as FDA issues OAI for Catalent site
NegativeFinancial Markets

Scholar Rock's stock has taken a hit following the FDA's issuance of an Official Action Indicated (OAI) for a Catalent manufacturing site. This development raises concerns about the production quality and regulatory compliance of the site, which could impact Scholar Rock's ability to deliver its products effectively. Investors are understandably worried, as regulatory issues can lead to delays and increased costs, affecting the company's overall performance.
— Curated by the World Pulse Now AI Editorial System